“We have the first device to treat macular telangiectasia type 2, which has been through the clinical trial program, and the long-term results up to 9 years find that it is still relatively well ...
The primary objective of this report is to describe the safety of long-term use of EryDex in treatment of pediatric patients with ataxia telangiectasia. Methods: This is a post-hoc analysis of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback